98%
921
2 minutes
20
Somatostatin (SST) and somatostatin receptors (SSTRs) play an important role in the brain and gastrointestinal (GI) system. SST is produced in various organs and cells, and the inhibitory function of somatostatin-containing cells is involved in a range of physiological functions and pathological modifications. The GI system is the largest endocrine organ for digestion and absorption, SST-endocrine cells and neurons in the GI system are a critical effecter to maintain homeostasis SSTRs 1-5 and co-receptors, while SST-SSTRs are involved in chemo-sensory, mucus, and hormone secretion, motility, inflammation response, itch, and pain the autocrine, paracrine, endocrine, and exoendocrine pathways. It is also a power inhibitor for tumor cell proliferation, severe inflammation, and post-operation complications, and is a first-line anti-cancer drug in clinical practice. This mini review focuses on the current function of producing SST endocrine cells and local neurons SST-SSTRs in the GI system, discusses new development prognostic markers, phosphate-specific antibodies, and molecular imaging emerging in diagnostics and therapy, and summarizes the mechanism of the SST family in basic research and clinical practice. Understanding of endocrines and neuroendocrines in SST-SSTRs in GI will provide an insight into advanced medicine in basic and clinical research.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009181 | PMC |
http://dx.doi.org/10.3389/fendo.2021.652363 | DOI Listing |
Rev Esp Med Nucl Imagen Mol (Engl Ed)
September 2025
Hospital Universitario Reina Sofía, IMIBIC, Universidad de Córdoba, Córdoba, Spain.
The use of theragnostics in nuclear medicine has significantly advanced, particularly peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Meningiomas often overexpress somatostatin receptors (SSTR), making them potential candidates for PRRT. However, the lack of large-scale standardized trials limits its clinical application.
View Article and Find Full Text PDFClin Nucl Med
September 2025
Department of Radiology, Division of Neuroradiology, University of Miami Miller School of Medicine, Jackson Memorial Hospital, Miami, FL.
The differential diagnosis of sinonasal lesions includes benign and malignant disease. Current radiologic diagnosis depends on the complementary roles of CT and MRI. PET/CT has been widely utilized for diagnosis and staging of various types of tumors as well as assessing treatment response.
View Article and Find Full Text PDFSci Rep
September 2025
Integrated Biomedical Sciences (IBMS) Program, The School of Medicine, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, TX, 78229, USA.
Temporomandibular joint (TMJ) disorders (TMJDs) are linked to heightened nerve sensitivity in TMJ tissues. To set the groundwork for investigating the mechanisms governing this increased responsiveness, this study aimed to identify the types of nerves in the retrodiscal tissue (retrodisc), anterior disc, and joint capsule of mouse TMJ using immunohistochemistry (IHC) and reporter mice. The pan-sensory neuronal marker pgp9.
View Article and Find Full Text PDFDrug Metab Dispos
August 2025
Department of Pharmacokinetics and Drug Metabolism, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland. Electronic address:
Our previous study showed that the antagonist of the GluN2B subunit of the N-methyl-D-aspartate (NMDA) receptor, the compound CP-101,606, negatively affected hepatic cytochrome P450 (P450) expression and activity after intraperitoneal administration. The aim of our current study was to demonstrate the effect of intracerebral administration of CP-101,606 into the paraventricular (PVN) or arcuate (ARC) nuclei of the hypothalamus on the central neuroendocrine regulation of P450. Male rats received bilateral injections of CP-101,606 into the PVN or ARC for 5 days.
View Article and Find Full Text PDFMedicina (Kaunas)
July 2025
Division of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.
: Peptide receptor radionuclide therapy (PRRT) using radiopharmaceuticals labelled with Lutetium-177 is currently a therapeutic option for patients with advanced neuroendocrine neoplasms overexpressing somatostatin receptors (SSTRs). One promising option that has gained interest for PRRT is using alpha-emitting radioisotopes such as Actinium-225. The aim of this study was to perform a systematic review and meta-analysis on the efficacy and safety of radioligand therapy with Actinium-225 DOTATATE in advanced, metastatic or inoperable neuroendocrine neoplasms.
View Article and Find Full Text PDF